監修

  • 谷口 浩也先生

    愛知県がんセンター中央病院
    薬物療法部 医長

  • 加藤 健先生

    国立がん研究センター中央病院 消化管内科 医長

  • 山﨑 健太郎先生

    静岡県立静岡がんセンター
    消化器内科 医長

レポーター (50音順)

  • 新井 裕之先生

    聖マリアンナ医科大学
    臨床腫瘍学 診療助手

  • 川上 尚人先生

    近畿大学医学部
    内科学腫瘍内科部門 医学部講師

  • 中島 雄一郎先生

    九州大学大学院
    消化器・総合外科 助教

  • 成田 有季哉先生

    愛知県がんセンター中央病院
    薬物療法部 医長

  • 宮本 敬大先生

    国立がん研究センター中央病院
    消化管内科 がん専門修練医

  • 山田 武史先生

    筑波大学附属病院
    消化器内科 病院講師

2017年6月2日~6日に米国シカゴで開催された、米国臨床腫瘍学会年次集会(2017 Annual Meeting of the American Society of Clinical Oncology®)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。

取材予定演題リスト

※本リストに掲載の演題は、発表前の限られた情報をもとに取材候補として選んだものです。
諸事情により、予告なく取材・掲載を取り止める場合がありますので、あらかじめご了承ください。

Colorectal Cancer

Oral Abstract #LBA1

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Qian Shi, et al.

Oral Abstract #3002

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Josep Tabernero, et al.

Oral Abstract #3500

Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

Thierry Andre, et al.

Oral Abstract #3501

FOLFOX4/XELOX in stage II-III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.

Alberto F. Sobrero, et al.

Oral Abstract #3502

Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.

Timothy Iveson, et al.

Oral Abstract #3503

Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Alan P. Venook, et al.

Oral Abstract #3505

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

Scott Kopetz, et al.

Oral Abstract #3506

SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.

Kimmie Ng, et al.

Oral Abstract #3510

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

Sebastian Stintzing, et al.

Oral Abstract #3511

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Heinz-Josef Lenz, et al.

Poster Abstract #3518

Comparison of long-term survival outcomes between laparoscopic and open surgery for mid or low rectal cancer treated with preoperative chemoradiotherapy: 7-year follow-up of COREAN trial.

Ji Won Park, et al.

Poster Abstract #3531

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

Thierry Andre, et al.

Poster Abstract #3540

Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.

Shota Fukuoka, et al.

Non-Colorectal Cancer

Oral Abstract #4001

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann-Lii Cheng, et al.

Oral Abstract #4003

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Charles S. Fuchs, et al.

Oral Abstract #4004

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Salah-Eddin Al-Batran, et al.

Oral Abstract #4006

Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.

John Neil Primrose, et al.

Oral Abstract #4008

Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

Sunil R. Hingorani, et al.

Oral Abstract #4014

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

Yelena Yuriy Janjigian, et al.

Poster Abstract #4010

ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC)-Efficacy and QOL results.

Keisuke Koeda, et al.

Poster Abstract #4012

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Yung-Jue Bang, et al.

Poster Abstract #4059

A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.

Katsunori Shinozaki, et al.